Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Jason Johansen‐Leete, Sven Ullrich, Sarah E. Fry, Rebecca L. Frkic, Max J. Bedding, Anupriya Aggarwal, Anneliese S. Ashhurst, Kasuni B. Ekanayake, Mithun C. Mahawaththa, Vishnu Mini Sasi, Stephanie Luedtke, Daniel Ford, Anthony J. O’Donoghue, Toby Passioura, Mark Larance, Gottfried Otting, Stuart Turville, Colin J. Jackson, Christoph Nitsche, Richard J. Payne
Abstract
RaPID mRNA display was used for the discovery of antiviral cyclic peptides that potently and selectively inhibit SARS-CoV-2 M pro . The most potent inhibitor exhibited a novel binding mode, interacting with residues across the homodimer interface.
Topics & Concepts
ProteaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakPandemicBiologyComputational biologyMedicineEnzymeBiochemistryInfectious disease (medical specialty)DiseasePathologyOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies